胰腺癌预后相关铁死亡基因筛选及预后预测模型构建

doi:10.3969/j.issn.1009-976X.2022.01.003

摘要/Abstract

摘要： 目的探讨铁死亡相关基因对胰腺癌患者预后预测的价值,并进一步探索其分子机制。方法从公共数据库中下载胰腺癌患者的基因表达及相应的临床病理数据,采用R软件“limma”包筛选胰腺癌组织中差异表达基因,使用单因素COX回归分析筛选预后相关的铁死亡相关基因,利用LASSO COX回归分析构建预后模型。通过Kaplan-Meier生存分析检验该模型在预测胰腺癌预后中的意义,用ROC曲线评估模型预测胰腺癌预后的准确性。在ICGC验证队列中通过Kaplan-Meier生存分析、ROC曲线评估该模型在外部队列中的预测价值。依照风险值中位数,将TCGA训练队列分为两组,比较其基因表达差异、差异基因富集通路差异,评估免疫细胞浸润丰度。结果通过单因素COX回归分析,37个铁死亡相关基因被鉴定为预后基因（P<0.05）。利用LASSO COX回归分析,构建了一个基于15个铁死亡相关基因的预后预测模型。根据模型计算将队列中所有患者分为高风险组和低风险组,Kaplan-Meier生存分析表明高风险组的胰腺癌患者较低风险组生存时间短（HR=2.16,P<0.05）。ROC曲线分析证明了预测模型在胰腺癌预后预测中的准确性：ROC曲线下面积值分别为0.74（1年）、0.82（3年）、0.88（5年）。对高低风险组差异表达基因进行功能富集分析,发现两组胰腺癌患者免疫微环境之间存在差异,高风险组中幼稚B细胞、浆细胞、CD8⁺T细胞浸润程度较低风险组低,但M0和M1巨噬细胞的浸润程度高（P<0.05）。此外,在PD-1和CTLA4在TCGA-PAAD队列低危组和高危组中的表达中,TCGA-PAAD队列低风险组患者中PD-1和CTLA4的表达水平较高风险组患者更高（P<0.05）。结论本研究构建了胰腺癌中铁死亡相关基因预后预测模型,具有预测胰腺癌患者预后的作用,并发现TCGA队列中高低风险组免疫微环境存在差异,可为免疫治疗提供参考。

关键词: 胰腺癌, 铁死亡, 预后

Abstract: Objective To explore the value of ferroptosis-related genes in predicting the prognosis of patients with pancreatic cancer, and further explore the potential molecular mechanism. Methods Gene expression and corresponding clinicopathological data of pancreatic cancer patients were downloaded from the public database. The differentially expressed genes in pancreatic cancer tissues were screened by R software “limma” package. Differentially expressed genes in pancreatic cancer tissues were verified by univariate COX regression analysis, and a prognostic model was established by LASSO COX regression analysis. We performed Kaplan-Meier survival analysis to examine the significance of the model in the prognosis of prediction pancreatic cancer. The accuracy of the model in the prognosis of prediction pancreatic cancer was analyzed by the ROC curve. In the ICGC verification queue, the predictive value of the model was evaluated by Kaplan-Meier survival analysis and ROC curve. Then we divided the TCGA-PAAD cohort into two groups according to the risk value, compared the differences in gene expression and gene enrichment pathways, and evaluated the abundance of immune cells in the tumor microenvironment. Results Thirty-seven ferroptosis related genes were identified as prognostic genes by univariate COX regression analysis. We constructed a prognostic model based on 15 iron death-related genes using LASSO COX regression analysis. According to the model calculation, all patients in the cohort were divided into the high-risk group and the low-risk group. Kaplan-Meier survival analysis suggested that the survival time of pancreatic cancer patients in the high-risk group was shorter than that in the low-risk group （HR=2.16, P<0.05）. ROC curve analysis proved the accuracy of the predictive model in predicting the prognosis of pancreatic cancer （the area under the ROC curve were 0.74 （1 year）, 0.82 （3 years）, and 0.88 （5 years）, respectively）. Functional enrichment analysis of differentially expressed genes in the high-risk and low-risk groups showed that there were significant differences in immune microenvironment between the two groups. The infiltration degrees of B naive cells, plasma cells, and CD8⁺T cells in the high-risk group were lower than that in the low-risk group, but the infiltration degrees of M0 and M1 macrophages were higher in the high-risk group than in the low-risk group（P<0.05）. In addition, we also studied the expression of PD-1 and CTLA4 in the low-risk group and high-risk group of the TCGA-PAAD cohort and found that the expression levels of PD-1 and CTLA4 in the low-risk group of the TCGA-PAAD cohort were higher than those in the high-risk group. Conclusion We have constructed a prognostic model of ferroptosis-related genes in pancreatic cancer, which can predict the prognosis of pancreatic cancer patients, and found that there are differences in immune microenvironment between the high-risk group and the low-risk group in the TCGA cohort, which can provide a reference for immunotherapy.

Key words: pancreatic cancer, ferroptosis, prognosis

中图分类号:

R735.9

何冲, 周姝睿, 李雅晴, 陈少杰, 练国达, 陈尚祥, 黄开红. 胰腺癌预后相关铁死亡基因筛选及预后预测模型构建[J]. 岭南现代临床外科, 2022, 22(01): 14-23.

HE Chong, ZHOU Shu-rui, LI Ya-qing, CHEN Shao-jie, LIAN Guo-da, CHEN Shang-xiang, HUANG Kai-hong. Screening of ferroptosis-related genes and construction of prognostic prediction model in pancreatic cancer[J]. Lingnan Modern Clinics In Surgery, 2022, 22(01): 14-23.

参考文献

[1] Siegel RL, Miller KD, Fuchs HE,et al.Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33.
[2] Zhu H, Li T, Du Y, et al.Pancreatic cancer: challenges and opportunities[J]. BMC Med, 2018, 16(1): 214.
[3] Stockwell BR, Jiang X, Gu W.Emerging Mechanisms and Disease Relevance of Ferroptosis[J]. Trends Cell Biol, 2020, 30(6): 478-490.
[4] Kremer DM, Nelson BS, Lin L, et al.GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis[J]. Nat Commun, 2021, 12(1): 4860.
[5] Gao H, Bai Y, Jia Y, et al.Ferroptosis is a lysosomal cell death process[J]. Biochem Biophys Res Commun, 2018, 503(3): 1550-1556.
[6] Hattori K, Ishikawa H, Sakauchi C, et al.Cold stress-induced ferroptosis involves the ASK1-p38 pathway[J]. EMBO Rep, 2017, 18(11): 2067-2078.
[7] Zhou Y, Zhou B, Pache L, et al.Metascape provides a biologist-oriented resource for the analysis of systems-level datasets[J]. Nat Commun, 2019, 10(1): 1523.
[8] Wang R, Su Q, Yin H, et al.Inhibition of SRSF9 enhances the sensitivity of colorectal cancer to erastin-induced ferroptosis by reducing glutathione peroxidase 4 expression[J]. Int J Biochem Cell Biol, 2021, 134: 105948.
[9] Yang Y, Luo M, Zhang K, et al.Nedd4 ubiquitylates VDAC2/3 to suppress erastin-induced ferroptosis in melanoma[J]. Nat Commun, 2020, 11(1): 433.
[10] Badgley MA, Kremer DM, Maurer HC, et al.Cysteine depletion induces pancreatic tumor ferroptosis in mice[J]. Science, 2020, 368(6486): 85-89.
[11] Xie Y, Hou W, Song X, et al.Ferroptosis: process and function[J]. Cell Death Differ, 2016, 23(3): 369-379.
[12] Zhang H, Deng T, Liu R, et al.CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer[J]. Mol Cancer, 2020, 19(1): 43.
[13] Wu Y, Zhang S, Gong X, et al.The epigenetic regulators and metabolic changes in ferroptosis-associated cancer progression[J]. Mol Cancer, 2020, 19(1): 39.
[14] Ousingsawat J, Schreiber R, Kunzelmann K.TMEM16F/Anoctamin 6 in Ferroptotic Cell Death[J]. Cancers (Basel), 2019, 11(5): 625.
[15] Gomaa A, Peng D, Chen Z, et al.Epigenetic regulation of AURKA by miR-4715-3p in upper gastrointestinal cancers[J]. Sci Rep, 2019, 9(1): 16970.
[16] Chatterjee M, Ben-Josef E, Thomas DG, et al.Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer[J]. Sci Rep, 2015, 5: 10867.
[17] Tarangelo A, Magtanong L, Bieging-Rolett KT, et al.p53 Suppresses Metabolic Stress-Induced Ferroptosis in Cancer Cells[J]. Cell Rep, 2018, 22(3): 569-575.
[18] Yuan H, Li X, Zhang X, et al.CISD1 inhibits ferroptosis by protection against mitochondrial lipid peroxidation[J]. Biochem Biophys Res Commun, 2016, 478(2): 838-844.
[19] Mittler R, Darash-Yahana M, Sohn YS, et al.NEET Proteins: A New Link Between Iron Metabolism, Reactive Oxygen Species, and Cancer[J]. Antioxid Redox Signal, 2019, 30(8): 1083-1095.
[20] Bai YT, Chang R, Wang H, et al.ENPP2 protects cardiomyocytes from erastin-induced ferroptosis[J]. Biochem Biophys Res Commun, 2018, 499(1): 44-51.
[21] Richter, K., Haslbeck, M, Buchner, J.The heat shock response: life on the verge of death[J]. Mol Cell, 2010, 40(2): 253-266.
[22] Sun X, Ou Z, Xie M, et al.HSPB1 as a novel regulator of ferroptotic cancer cell death[J]. Oncogene, 2015, 34(45): 5617-5625.
[23] Hou W, Xie Y, Song X, et al.Autophagy promotes ferroptosis by degradation of ferritin[J]. Autophagy, 2016, 12(8): 1425-1428.
[24] Dietrich P, Gaza A, Wormser L, et al.Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma[J]. Neoplasia, 2019, 21(3): 257-268.
[25] Gentric G, Kieffer Y, Mieulet V, et al. PML-Regulated Mitochondrial Metabolism Enhances Chemosensitivity in Human Ovarian Cancers [J]. Cell Metab, 2019, 29(1): 156-73.e10.
[26] Brown CW, Amante JJ, Chhoy P, et al. Prominin2 Drives Ferroptosis Resistance by Stimulating Iron Export [J]. Dev Cell, 2019, 51(5): 575-86.e4.
[27] Liu X, Qi K, Gong Y, et al.Ferulic acid alleviates myocardialischemia reperfusioninjury via upregulating AMPKα2 expression-mediated ferroptosis depression[J]. J Cardiovasc Pharmacol, 2021. doi: 10.1097/FJC.0000000000001199.
[28] Yang Y, Lin J, Guo S, et al.RRM2 protects against ferroptosis and is a tumor biomarker for liver cancer[J]. Cancer Cell Int, 2020, 20(1): 587.
[29] Yang W, Liu H, Duan B, et al.Three novel genetic variants in NRF2 signaling pathway genes are associated with pancreatic cancer risk[J]. Cancer Sci, 2019, 110(6): 2022-2032.
[30] Li Y, Feng D, Wang Z, et al.Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion[J]. Cell Death Differ, 2019, 26(11): 2284-2299.
[31] Wang W, Green M, Choi JE, et al.CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy[J]. Nature, 2019, 569(7755): 270-274.
[32] Henriksen A, Dyhl-Polk A, Chen I, et al.Checkpoint inhibitors in pancreatic cancer[J]. Cancer Treat Rev, 2019, 78: 17-30.